TP53 and myelodysplastic syndrome: In conclusion, the microenvironment of TP53 mutant MDS and sAML has an immune-privileged, aversive phenotype that is a major contributor to a poor prognosis, suggesting that immunomodulatory treatment strategies may be effective in the future.